MA43913A - Modulateurs allostériques positifs du récepteur m1 muscarinique - Google Patents

Modulateurs allostériques positifs du récepteur m1 muscarinique

Info

Publication number
MA43913A
MA43913A MA043913A MA43913A MA43913A MA 43913 A MA43913 A MA 43913A MA 043913 A MA043913 A MA 043913A MA 43913 A MA43913 A MA 43913A MA 43913 A MA43913 A MA 43913A
Authority
MA
Morocco
Prior art keywords
muscarinic
receptor
positive allosteric
allosteric modulators
compounds
Prior art date
Application number
MA043913A
Other languages
English (en)
Other versions
MA43913B1 (fr
Inventor
Shankar Reddy Gagginapally
Venkateswarlu Jasti
Abdul Rasheed Mohammed
Ramakrishna Nirogi
Anil Karbhari Shinde
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MA43913A publication Critical patent/MA43913A/fr
Publication of MA43913B1 publication Critical patent/MA43913B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Arrangement And Driving Of Transmission Devices (AREA)
  • Liquid Crystal Display Device Control (AREA)

Abstract

La présente invention concerne un composé de formule (i), ou des stéréoisomères et des sels pharmaceutiquement acceptables en tant que modulateurs allostériques positifs pour le récepteur m1 muscarinique. Cette invention concerne également des procédés de préparation de tels composés et des compositions pharmaceutiques comprenant ces composés. Les composés de cette invention sont utiles dans le traitement de divers troubles liés au récepteur muscarinique m1.
MA43913A 2015-06-08 2016-06-08 Modulateurs allostériques positifs du récepteur m1 muscarinique MA43913B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2851CH2015 2015-06-08
PCT/IB2016/000771 WO2016198937A1 (fr) 2015-06-08 2016-06-08 Modulateurs allostériques positifs du récepteur muscarinique m1
EP16738860.2A EP3303331B1 (fr) 2015-06-08 2016-06-08 Modulateurs allostériques positifs du récepteur m1 muscarinique

Publications (2)

Publication Number Publication Date
MA43913A true MA43913A (fr) 2018-04-11
MA43913B1 MA43913B1 (fr) 2019-05-31

Family

ID=56411822

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43913A MA43913B1 (fr) 2015-06-08 2016-06-08 Modulateurs allostériques positifs du récepteur m1 muscarinique

Country Status (29)

Country Link
US (1) US10308620B2 (fr)
EP (1) EP3303331B1 (fr)
JP (1) JP6466602B2 (fr)
KR (1) KR102052058B1 (fr)
CN (1) CN107922400B (fr)
AU (1) AU2016276139B2 (fr)
BR (1) BR112017026272B1 (fr)
CA (1) CA2987843C (fr)
CY (1) CY1121693T1 (fr)
DK (1) DK3303331T3 (fr)
EA (1) EA032602B1 (fr)
ES (1) ES2719626T3 (fr)
HR (1) HRP20190624T1 (fr)
HU (1) HUE044902T2 (fr)
IL (1) IL255994B (fr)
LT (1) LT3303331T (fr)
MA (1) MA43913B1 (fr)
MD (1) MD3303331T2 (fr)
ME (1) ME03379B (fr)
MX (1) MX2017015961A (fr)
NZ (1) NZ737892A (fr)
PL (1) PL3303331T3 (fr)
PT (1) PT3303331T (fr)
RS (1) RS58665B1 (fr)
SI (1) SI3303331T1 (fr)
SM (1) SMT201900213T1 (fr)
TR (1) TR201904639T4 (fr)
WO (1) WO2016198937A1 (fr)
ZA (1) ZA201708108B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077517A1 (fr) * 2017-10-18 2019-04-25 Suven Life Sciences Limited Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
NZ763341A (en) * 2017-10-27 2023-03-31 Suven Life Sciences Ltd Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
WO2020206410A1 (fr) * 2019-04-04 2020-10-08 University Of Maryland, Baltimore Procédés d'utilisation d'antagonistes muscariniques dans le traitement de la dépression
KR102285472B1 (ko) 2019-06-14 2021-08-03 엘지전자 주식회사 음향의 이퀄라이징 방법과, 이를 구현하는 로봇 및 ai 서버
CN110606827B (zh) * 2019-09-26 2023-03-14 西安凯立新材料股份有限公司 一步法合成甲氨基吡啶类化合物的方法
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (fr) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide; derives
WO2007100366A2 (fr) 2005-12-05 2007-09-07 Merck & Co., Inc. Modulateurs allostériques positifs du récepteur de la quinolone m1
WO2011149801A1 (fr) 2010-05-28 2011-12-01 Merck Sharp & Dohme Corp. Composés de naphthalène carboxamide, modulateurs allostériques positifs du récepteur m1
JP2014076948A (ja) 2011-02-09 2014-05-01 Astellas Pharma Inc イソキノリンアミド誘導体
EP2821401B1 (fr) * 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Composés de dihydroquinolinone en tant que modulateurs du récepteur muscarinique m1
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015080904A1 (fr) * 2013-11-27 2015-06-04 Vanderbilt University Analogues substitués du 4-benzyl-3,4-dihydro-2h-benzo[b] [1,4] oxazine-2-carboxamide, utilisés comme modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
GB201409044D0 (en) * 2014-05-21 2014-07-02 Ucl Business Plc New compounds

Also Published As

Publication number Publication date
ES2719626T3 (es) 2019-07-11
PL3303331T3 (pl) 2019-06-28
EP3303331B1 (fr) 2019-02-27
SMT201900213T1 (it) 2019-05-10
RS58665B1 (sr) 2019-06-28
HK1247919A1 (zh) 2018-10-05
PT3303331T (pt) 2019-04-30
IL255994A (en) 2018-01-31
CY1121693T1 (el) 2020-07-31
EP3303331A1 (fr) 2018-04-11
CN107922400A (zh) 2018-04-17
TR201904639T4 (tr) 2019-05-21
EA201792594A1 (ru) 2018-06-29
LT3303331T (lt) 2019-04-25
CA2987843C (fr) 2020-07-14
MX2017015961A (es) 2018-07-06
MA43913B1 (fr) 2019-05-31
DK3303331T3 (en) 2019-04-23
NZ737892A (en) 2018-09-28
ZA201708108B (en) 2018-11-28
US10308620B2 (en) 2019-06-04
BR112017026272A2 (pt) 2018-09-11
IL255994B (en) 2018-04-30
BR112017026272B1 (pt) 2023-04-11
JP2018521024A (ja) 2018-08-02
AU2016276139B2 (en) 2018-07-19
SI3303331T1 (sl) 2019-05-31
EA032602B1 (ru) 2019-06-28
WO2016198937A1 (fr) 2016-12-15
MD3303331T2 (ro) 2019-05-31
HUE044902T2 (hu) 2019-11-28
KR20180016528A (ko) 2018-02-14
KR102052058B1 (ko) 2019-12-04
HRP20190624T1 (hr) 2019-05-31
US20180155302A1 (en) 2018-06-07
ME03379B (fr) 2020-01-20
AU2016276139A1 (en) 2018-01-04
CN107922400B (zh) 2021-05-11
JP6466602B2 (ja) 2019-02-06
CA2987843A1 (fr) 2016-12-15

Similar Documents

Publication Publication Date Title
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA42292A (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA40254B1 (fr) Polymorphes du selinexor
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires